Changes of Mycobacterium Tuberculosis Specific Antigen-stimulated CD27CD38IFN-γCD4 T Cells Before and After Anti-tuberculosis Treatment

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Mar 1

PMID 38429734

Authors

Yong Fang

Yuan Tang

Qiao-Xia Luo

Na Wang

Liang Tang

Xiao-Jun Yang

Xiao-Fang You

Yu-Chun Wang

Li Liang

Jing-Bo Zhang

Bo Su

Wei Sha

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the study was to investigate whether the expression of CD27CD38 in interferon (IFN)-γCD4 T cells stimulated by the specific antigen early secreted antigenic target-6 (ESAT-6)/culture filter protein-10 (CFP-10) could be a potential new therapeutic evaluation indicator for anti-tuberculosis (TB) treatment.

Methods: Newly diagnosed active pulmonary TB patients, latent TB infection (LTBI) and healthy controls were enrolled from January 2021 to December 2021. PTB patients were treated by standard anti-TB regimen 2HREZ/4HR (2 months of isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (Z) followed by 4 months of isoniazid (H) and rifampin (R)). The difference of CD27CD38 expression in IFN-γCD4 T cells before treatment, 2 months after treatment, and 6 months after treatment were compared.

Results: Total 45 PTB patients, 38 LTBI cases and 43 healthy controls were enrolled. The expression of CD27CD38 decreased significantly after anti-TB treatment and was comparable with that in LTBI and healthy controls when the 6-month anti-TB treatment course was completed. The decline rate of CD27CD38 between 6 months after treatment and baseline was positively correlated with erythrocyte sedimentation rate (r = 0.766, P < 0.0001), C-reactive protein (r = 0.560, P = 0.003) and chest computerized tomography severity score (r = 0.632, P = 0.0005). The area under receiver operator characteristic curve of CD27CD38 in distinguish pulmonary TB patients before and after treatment was 0.779.

Conclusion: The expression of CD27CD38 in ESAT-6/CFP-10 stimulated IFN-γCD4T cells can well reflect the changes of the disease before and after anti-TB treatment, which is expected to be a potential new therapeutic evaluation index. Clinical Registry number chiCTR1800019966.

References

Chiappini E, Bonsignori F, Mangone G, Galli L, Mazzantini R, Sollai S . Serial T-SPOT.TB and quantiFERON-TB-Gold In-Tube assays to monitor response to antitubercular treatment in Italian children with active or latent tuberculosis infection. Pediatr Infect Dis J. 2012; 31(9):974-7. DOI: 10.1097/INF.0b013e31825d0d67. View

Kager L, Blok D, Lede I, Rahman W, Afroz R, Bresser P . Pulmonary tuberculosis induces a systemic hypercoagulable state. J Infect. 2014; 70(4):324-34. DOI: 10.1016/j.jinf.2014.10.006. View

Sahle E, Blumenthal J, Jain S, Sun S, Young J, Manyazewal T . Bacteriologically-confirmed pulmonary tuberculosis in an Ethiopian prison: Prevalence from screening of entrant and resident prisoners. PLoS One. 2019; 14(12):e0226160. PMC: 6907752. DOI: 10.1371/journal.pone.0226160. View

Vickers M, Darboe F, Muefong C, Mbayo G, Barry A, Gindeh A . Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Specific T Cell Activation and Functional Markers. Front Immunol. 2021; 11:572620. PMC: 7931252. DOI: 10.3389/fimmu.2020.572620. View

Latorre I, Fernandez-Sanmartin M, Muriel-Moreno B, Villar-Hernandez R, Vila S, De Souza-Galvao M . Study of CD27 and CCR4 Markers on Specific CD4 T-Cells as Immune Tools for Active and Latent Tuberculosis Management. Front Immunol. 2019; 9:3094. PMC: 6334476. DOI: 10.3389/fimmu.2018.03094. View

Ahmed M, Ntinginya N, Kibiki G, Mtafya B, Semvua H, Mpagama S . Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy. Front Immunol. 2018; 9:2247. PMC: 6172348. DOI: 10.3389/fimmu.2018.02247. View

Adekambi T, Ibegbu C, Cagle S, Kalokhe A, Wang Y, Hu Y . Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest. 2015; 125(5):1827-38. PMC: 4598074. DOI: 10.1172/JCI77990. View

Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya N . Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis. 2014; 14(10):931-8. DOI: 10.1016/S1473-3099(14)70884-9. View

Malacarne J, Heirich A, Cunha E, Kolte I, Souza-Santos R, Basta P . Performance of diagnostic tests for pulmonary tuberculosis in indigenous populations in Brazil: the contribution of Rapid Molecular Testing. J Bras Pneumol. 2019; 45(2):e20180185. PMC: 6733740. DOI: 10.1590/1806-3713/e20180185. View

10.

Heyckendorf J, Georghiou S, Frahm N, Heinrich N, Kontsevaya I, Reimann M . Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clin Microbiol Rev. 2022; 35(3):e0022721. PMC: 9491169. DOI: 10.1128/cmr.00227-21. View

11.

Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S, Jaxa L . T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.00153-2018. View

12.

Clifford V, He Y, Zufferey C, Connell T, Curtis N . Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review. Tuberculosis (Edinb). 2015; 95(6):639-650. DOI: 10.1016/j.tube.2015.07.002. View

13.

Combs D, OBrien R, Geiter L . USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990; 112(6):397-406. DOI: 10.7326/0003-4819-76-3-112-6-397. View

14.

Lyon S, Rossman M . Pulmonary Tuberculosis. Microbiol Spectr. 2017; 5(1). PMC: 11687454. DOI: 10.1128/microbiolspec.TNMI7-0032-2016. View

15.

Ma S, Zhou Z, Wan Z, Duan P, Huang S, Xu J . Osteotomized debridement versus curetted debridement in posterior approach in treating thoracolumbar tuberculosis: a comparative study. Eur Spine J. 2022; 31(2):473-481. DOI: 10.1007/s00586-021-07075-w. View

16.

Xu F, Zhang H, Si X, Chen J, Chen Y, Cui X . Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis. BMC Immunol. 2021; 22(1):41. PMC: 8237462. DOI: 10.1186/s12865-021-00430-y. View

17.

Riou C, Berkowitz N, Goliath R, Burgers W, Wilkinson R . Analysis of the Phenotype of -Specific CD4+ T Cells to Discriminate Latent from Active Tuberculosis in HIV-Uninfected and HIV-Infected Individuals. Front Immunol. 2017; 8:968. PMC: 5554366. DOI: 10.3389/fimmu.2017.00968. View

18.

Silveira-Mattos P, Barreto-Duarte B, Vasconcelos B, Fukutani K, Vinhaes C, Oliveira-de-Souza D . Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. Clin Infect Dis. 2019; 71(8):1905-1911. PMC: 8463092. DOI: 10.1093/cid/ciz1070. View

19.

Halliday A, Whitworth H, Kottoor S, Niazi U, Menzies S, Kunst H . Stratification of Latent Mycobacterium tuberculosis Infection by Cellular Immune Profiling. J Infect Dis. 2017; 215(9):1480-1487. PMC: 5451604. DOI: 10.1093/infdis/jix107. View

20.

Sproston N, Ashworth J . Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018; 9:754. PMC: 5908901. DOI: 10.3389/fimmu.2018.00754. View